Eyenovia Revenue and Competitors
Estimated Revenue & Valuation
- Eyenovia's estimated annual revenue is currently $10.5M per year.
- Eyenovia's estimated revenue per employee is $155,000
Employee Data
- Eyenovia has 68 Employees.
- Eyenovia grew their employee count by 3% last year.
Eyenovia's People
| Name | Title | Email/Phone |
|---|
Eyenovia Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 4 | -20% | N/A | N/A |
#2 | $6.7M | 43 | 8% | N/A | N/A |
#3 | $34.4M | 222 | -1% | N/A | N/A |
#4 | $5.2M | 67 | 0% | $10M | N/A |
#5 | $2M | 13 | 0% | N/A | N/A |
#6 | $7.5M | 37 | 0% | $51.6M | N/A |
#7 | $0.3M | 2 | -50% | N/A | N/A |
#8 | $4.3M | 21 | -16% | $3.3M | N/A |
#9 | $3.6M | 23 | 0% | N/A | N/A |
#10 | $4.3M | 56 | -8% | $118M | N/A |
What Is Eyenovia?
Eyenovia, Inc. (NASDAQ: EYEN) is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for microdosing. Eyenoviaￃﾢ￢ﾂﾬ￢ﾄﾢs pipeline is currently focused on the late-stage development of microdosed medications for myopia progression, glaucoma, mydriasis and other eye diseases.
keywords:N/A
N/A
Total Funding
68
Number of Employees
$10.5M
Revenue (est)
3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Eyenovia News
Eyenovia CEO, CMO and Chairman Dr. Sean Ianchulev to Present at Eyecelerator American Society of Cataract and Refractive Surgery (ASCRS)...
NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a...
Eyenovia, Inc. (NASDAQ: EYEN) is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP)...
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $8.3M | 68 | -32% | $33.1M |
#2 | $13.5M | 68 | -28% | N/A |
#3 | $9.2M | 68 | 6% | N/A |
#4 | $7.3M | 68 | 28% | N/A |
#5 | $8.9M | 68 | 3% | N/A |